Latest News and Press Releases

Myriad Genetics announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country - Analysis and Forecast, 2024-2033" report has been added to ...

US & Canada, March 26, 2025 (GLOBE NEWSWIRE) -- According to a comprehensive report from The Insight Partners, “Direct-To-Consumer Genetic Testing Market Size and Forecast (2025–2031), Global...

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory celebrating a decade at the forefront of genetic testing, today shared research on the value of both...

Myriad Genetics announced a collaboration with Gabbi to provide an integrated offering for breast cancer risk assessment.

Dublin, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The "China Genetic Testing Market by Test Type, Disease, Technology, Service Provider, Testing Sample 2025-2033" report has been added to ...

Myriad Genetics announces senior leadership transition; Sam Raha as CEO and Mark S. Verratti as COO effective April 30, 2025.

Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.

Myriad Genetics has been named on the Forbes list of America’s Best Employers 2025.

Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025.